Mimedx (MDXG) Revenue (2011 - 2026)
Mimedx (MDXG) posted Revenue of $64.4 million for Q2 2026, up 9.1% sequentially from $59.0 million in Q1 2026, and down 34.73% YoY from $98.6 million in Q2 2025.
Mimedx (MDXG) Revenue (2011 - 2026) Analysis & Trends
Mimedx has reported Revenue for 16 years, with the latest figure at $64.4 million in Q2 2026.
- Quarterly Revenue fell 34.73% year-over-year to $64.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $355.2 million (down 2.36% YoY) and the FY2025 annual result came in at $418.6 million, up 19.99% from the prior year.
- Revenue rose to $64.4 million in Q2 2026 per MDXG's latest filing, from $59.0 million in the prior quarter.
- Over five years, Revenue peaked at $118.1 million in Q4 2025 and troughed at $58.9 million in Q1 2022.
- A 5-year average of $82.2 million and a median of $82.9 million in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2022 and 2026: Revenue surged 46.37% in 2022, then tumbled 34.73% in 2026.
- Over 5 years, Revenue stood at $74.4 million in 2022, then advanced by 16.75% to $86.8 million in 2023, then climbed by 7.0% to $92.9 million in 2024, then grew by 27.11% to $118.1 million in 2025, then sank by 45.5% to $64.4 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $64.4 million, $59.0 million, and $118.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 64.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.36 Mn |
| Mar 31, 2026 | 58.99 Mn |
| Dec 31, 2025 | 118.10 Mn |
| Sep 30, 2025 | 113.73 Mn |
| Jun 30, 2025 | 98.61 Mn |
| Mar 31, 2025 | 88.21 Mn |
| Dec 31, 2024 | 92.91 Mn |
| Sep 30, 2024 | 84.06 Mn |
| Jun 30, 2024 | 87.21 Mn |
| Mar 31, 2024 | 84.71 Mn |
| Dec 31, 2023 | 86.83 Mn |
| Sep 30, 2023 | 81.71 Mn |
| Jun 30, 2023 | 81.26 Mn |
| Mar 31, 2023 | 71.68 Mn |
| Dec 31, 2022 | 74.38 Mn |
| Sep 30, 2022 | 67.69 Mn |
| Jun 30, 2022 | 66.88 Mn |
| Mar 31, 2022 | 58.89 Mn |
| Dec 31, 2021 | 50.81 Mn |
| Sep 30, 2021 | 63.07 Mn |